Journal of Thrombosis and Thrombolysis

, Volume 44, Issue 4, pp 466–474 | Cite as

Comparison of 4 different strategies of DAPT after PCI in ACS real world population from a Northern Italy registry

  • Marta Rasia
  • Emilia Solinas
  • Massimiliano Marino
  • Paolo Guastaroba
  • Alberto Menozzi
  • Maria Alberta Cattabiani
  • Iacopo Tadonio
  • Rossana De Palma
  • Luigi Vignali


Aim of the study was to compare four different strategies of dual antiplatelet therapy (DAPT) in patients with acute coronary syndromes (ACS) treated with PCI. DAPT with Clopidogrel, Ticagrelor and Prasugrel has proved to be effective in patients with ACS treated with percutaneous coronary intervention (PCI) by reducing major adverse cardiovascular outcomes (MACE). However, the effect of the different strategies in a real-world population deserves further verification. A retrospective analysis of 2404 discharged ACS patients treated with PCI was performed, with a median follow-up of 1 year. The study population was stratified in four drug treatment cohorts: ASA + Clopidogrel (A-C), ASA + Plavix (A-PLx), ASA + Ticagrelor (A-T), ASA + Prasugrel (A-P). We assessed the incidence of net adverse cardiovascular events (NACE): all-cause death, myocardial infarction (MI), target vessel revascularization (TVR), stroke and bleeding during follow-up. At 1-year, the use of A-C and A-PLx was associated with the highest cumulative incidence of NACE in comparison with A-T and A-P therapies (respectively 14.8 and 29.6% vs. 9.2 and 6%). This difference was mainly driven by the mortality and TVR outcomes. Considering selection bias and differences in the patients baseline characteristics, the association of A-T and A-P seems to be superior in comparison with a DAPT strategy of A-C and A-PLx in low risk ACS-PCI patients from real world. In our Region the prescription is consistent with guidelines recommendations and Clopidogrel and Plavix are still predominantly used in older patients with more comorbidities, and this could partially explain the inferiority of this association.


Acute coronary syndromes Double antiplatelet therapy P2Y12 inhibitors 


Compliance with ethical standards

Conflict of interest

All authors have no conflict of interest to declare.

Ethical approval

This article does not contain any studies with human participants or animals performed by any of the authors.


  1. 1.
    Mehta SR, Yusuf S (2000 Dec) Clopidogrel in unstable angina to prevent recurrent events (CURE) study investigators. The Clopidogrel in unstable angina to prevent recurrent events (CURE) trial programme; rationale, design and baseline characteristics including a meta-analysis of the effects of thienopyridines in vascular disease. Eur Heart J 21(24):2033–2041CrossRefPubMedGoogle Scholar
  2. 2.
    James S, Akerblom A, Cannon CP, Emanuelsson H, Husted S, Katus H, Skene A, Steg PG, Storey RF, Harrington R, Becker R, Wallentin L (2009) Comparison of ticagrelor, the first reversible oral P2Y12 receptor antagonist, with Clopidogrel in patients with acute coronary syndromes: rationale, design, and baseline characteristics of the PLATelet inhibition and patient outcomes (PLATO) trial. Am Heart J 157(4):599–605. doi: 10.1016/j-ahj.2009.01.003 CrossRefPubMedGoogle Scholar
  3. 3.
    Bonaca MP, Goto S, Bhatt DL, Steg PG, Storey RF, Cohen M, Goodrich E, Mauri L, Ophuis TO, Ruda M, Spinar J, Seung KB, Hu D, Dalby AJ, Jensen E, Held P, Morrow DA, Braunwald E, Sabatine MS (2016 Sep) Prevention of stroke with ticagrelor in patients with prior Myocardial infarction: insights from PEGASUS-TIMI 54 (prevention of cardiovascular events in patients with prior heart attack using ticagrelor compared to placebo on a background of aspirin-thrombolysis in myocardial infarction 54). Circulation 20(12):86171. doi: 10.1161/CIRCULATIONAHA.116.024637 Google Scholar
  4. 4.
    Bonaca MP, Wiviott SD, Braunwald E, Murphy SA, Ruff CT, Antman EM, Morrow DA (2012) American College of Cardiology/American Heart Association/European Society of cardiology/World Heart Federation universal definition of myocardial infarction classification system and the risk of cardiovascular death: observations from the TRITON-TIMI 38 trial (trial to assess improvement in therapeutic outcomes by optimiziong platelet inhibition with prasugrel-thrombolysis in myocardial infarction 38). Circulation 125(4):577–583. doi: 10.1161/CIRCULATION.111.041160 CrossRefPubMedGoogle Scholar
  5. 5.
    Steg G, James SK, Atar D, Badano LP, Lundqvist CB, Borger MA, Di Mario C, Dickstein K, Ducrocq G, Fernandez-Aviles F, Gershlick AH, Giannuzzi P, Halvorsen S, Huber K, Juni P, Kastrati A, Knuuti J, Lenzen MJ, Mahaffey KW, Valgimigli M, van’t Hof A, Widimsky P, Zahger D (2012) Committee for practise guidelines ESC. (CPG) ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation: the task force on the management of ST-segment elevation acute myocardial infarction of the European Society of CARDIOLOGY (ESC). Eur Heart J 33:2569–2619CrossRefPubMedGoogle Scholar
  6. 6.
    Roffi M, Patrono C, Collet J-P, Mueller C, Valgimigli M, Andreotti F, Bax JJ, Borger MA, Brotons C, Chew DP, Gencer B, Hasenfuss G, Kjeldsen K, Lancellotti P, Landmesser U, Mehilli J, Mukherjee D, Storey RF, Windecker S (2016) 2015 ESC guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation. Eur Heart J 37:267–315. doi: 10.1093/eurheartj/ehv320 CrossRefPubMedGoogle Scholar
  7. 7.
    Green A, Pottegard A, Broe A, Diness TG, Emneus M, Hasvold P, Gislason GH (2016) Initiation and persistence with dual antiplatelet therapy after acute myocardial infarction: a Danish nationwide population-based cohort study. BMJ Open 6(5):e010880. doi: 10.1136/bmjopen-2015-010880 CrossRefPubMedPubMedCentralGoogle Scholar
  8. 8.
    Alexopoulos D, Xanthopoulou I, Deftereos S, Hamilos M, Sitafidis G, Kanakakis I, Pentara I, Vavouranakis M, Davlouros M, P., Hahalis G, Goudevenos J (2016) Contemporary antiplatelet treatment in acute coronary syndrome patients undergoing percutaneous coronary intervention: 1-year outcomes from the Greek AntiPlatElet (GRAPE) registry. J Thromb Haemost 14(6):1146–1154. doi: 10.1111/jth.13316 CrossRefPubMedGoogle Scholar
  9. 9.
    Yudi MB, Clark DJ, Farouque O, Eccleston D, Andrianopoulos N, Duffy SJ, Brennan A, Lefkovits J, Ramchand J, Yip T, Oqueli E, Reid CM, Ajani AE, Melbourne Interventional Group (2016) Clopidogrel, prasugrel or ticagrelor in patients with acute coronary syndromes undergoing percutaneous coronary intervention. Inter Med J 46(5):559–565. Doi: 10.1111/imj.13041 CrossRefGoogle Scholar
  10. 10.
    Rezaei SS, Geroldinger A, Heinze G, Reichardt B, Wolzt M (2017) Clopidogrel, prasugrel, or ticagrelor use and clinical outcome in patients with acute coronary syndrome: A nationwide long-term registry analysis from 2009 to 2014. Int J Cardiol 235:61–66. doi: 10.1016/j.ijcard.2017.02.096 CrossRefGoogle Scholar
  11. 11.
    Larmore C, Effron MB, Molife C, DeKoven M, Zhu Y, Lu J, Karkare S, Lieu HD, Lee WC, Vetrovec GW (2016) “Real-world” comparison of Prasugrel With Ticagrelor in patients With acute coronary syndrome treated with percutaneous coronary intervention in the United States. Catheter Cardiovasc Interv 88(4):535–544(2016)CrossRefPubMedGoogle Scholar
  12. 12.
    Sucato V, Corrado E, Castellana C, Carella M, Raso S, Coppola G, Andolina G, Novo G, Evola S, Novo S (2017 Jun) Real-world use of ticagrelor and prasugrel in patients with NSTEMI undergoing percutaneous coronary intervention. J Cardiovasc Med (Hagerstown) 18(6):450–451. doi: 10.2459/JCM.0000000000000516 CrossRefGoogle Scholar
  13. 13.
    Biondi-Zoccai G, Lotrione M, Agostoni P, Abbate A, Romagnoli E, Sangiorgi G, Angiolillo DJ, Valgimigli M, Testa L, Gaita F, Sheiban I (2011) Adjusted indirect comparison meta-analysis of prasugrel versus ticagrelor for patients with acute coronary syndromes. Int Cardiol 150:325–331CrossRefGoogle Scholar
  14. 14.
    Chatterjee S, Ghose A, Sharma A, Guha G, Mukherjee D, Frankel R (2013) Comparing newer oral anti-platelets prasugrel and ticagrelor in reduction of ischemic events-evidence from a network meta-analysis. J Thromb Thrombolysis 36:223–232CrossRefPubMedGoogle Scholar
  15. 15.
    Wallentin L, Varenhorst C, James S, Erlinge D, Braun OO, Jakubowski JA, Sugidachi A, Winters KJ, Siegbahn A (2008) Prasugrel achives greater and faster P2Y12receptor-mediated platelet inhibition than Clopidogrel due to more efficient generation of its active metabolite in aspirin-treated patients with coronary artery disease. Eur Heart J 29:21–30. doi: 10.1093/eurheartj/ehm545 CrossRefPubMedGoogle Scholar
  16. 16.
    Gurbel PA, Bliden KP, Butler K, Tantry US, Gesheff T, Wei C, Teng R, Antonino MJ, Patil SB, Karunakaran A, Kereiakes DJ, Parris C, Purdy D, Wilson V, Ledley GS, Storey RF (2009) Randomized double-blinded assessment of the ONSET and OFFSET of the antiplatelet effects of tocagrelor versus Clopidogrel in patients with stable coronary artery disease: the ONSET/OFFSET study. Circulation 120:2577–2585. doi: 10.1161/CIRCULATIONAHA.109.912550 CrossRefPubMedGoogle Scholar
  17. 17.
    Motovska Z, Ondrakova M, Bednar F, Knot J, Ulman J, Maly M (2015) Selection of P2Y12 antagonist, treatment initiation, and predictors of high on-treatment platelet reactivity in a “real world” registry. Thromb Res 135:1093–1099. doi: 10.1016/j.thromres.2015.04.014 CrossRefPubMedGoogle Scholar
  18. 18.
    Franchi F, Rollini F, Aggarwal N, Hu J, Kureti M, Durairaj A, Duarte VE, Cho JR, Been L, Zenni MM, Bass TA, Angiolillo DJ (2016) Pharmacodynamic comparison of prasugrel versus ticagrelor in patients with type 2 diabetes mellitus and coronary artery disease: the OPTIMUS (optimizing antiplatelet therapy in diabetes mellitus)-4 study. Circulation 134(11):780–792CrossRefPubMedGoogle Scholar
  19. 19.
    Ntalas I, Kalantzi K, Tsoumani M, Vakalis J, Vasilakopoulos V, Vardakis K, Vemmos K, Voukelatou M, Giannakoulas G, Giatrakos I, Giogiakas V (2015) Generic Clopidogrel besylate in the secondary prevention of atherothrombotic events: a 6-month follow-up of a randomised clinical trial. Curr Vasc Pharmacol 13(6):809–818CrossRefPubMedGoogle Scholar
  20. 20.
    Hamilos M, Saloustros I, Skalidis E, Igoumenidis N, Kambouris M, Chlouverakis G, Vougia D, Loggakis I, Vardas PE, Kochiadakis G (2015) Comparison of the antiplatelet effect of Clopidogrel hydrogenosulfate and Clopidogrel besylate in patients with stable coronary artery disease. J Thromb Thrombolysis 40(3): 288 – 93. Doi: 10.1007/s11239-015-1173-y
  21. 21.
    Seo KW, Tahk SJ, Yang HM, Yoon MH, Shin JH, Choi SY, Lim HS, Hwang GS, Choi BJ, Park JS, Shin JS (2014) Point-of care Measurements of Platelet Inhibition After Clopidogrel Loading in patients With Acute Coronary Syndrome: Comparison of Generic and Branded Clopidogrel Bisulfate. Clin Ther 36(11):1588–1594. Doi: 10.1016/j.clinthera.2014.07.018 CrossRefPubMedGoogle Scholar
  22. 22.
    Ntalas IV, Kalantzi KI, Tsoumani ME, Bourdakis A, Charmpas C, Christogiannis Z, Dimoulis N, Draganigos A, Efthimiadis I, Giannakoulas G, Giatrakos I (2016) Salts of Clopidogrel: investigation to ensure clinical equivalence: a 12-month randomized clinical trial. J Cardiovasc Pharmacol Ther 21(6):516–525CrossRefPubMedGoogle Scholar
  23. 23.
    Khosravi AR1, Pourmoghadas M, Ostovan M, Mehr GK, Gharipour M, Zakeri H, Soleimani B, Namdari M, Hassanzadeh M, Tavassoli AA, Ghaffari S, Khaledifar A, Roghani F, Khosravi MR, Sarami S, Kojouri J, Nori F, Khosravi E, Jozan M, Sarrafzadegan N. The impact of generic form of Clopidogrel on cardiovascular events in patients with coronary artery stent: results of the OPCES study. J Res Med Sci 2011; 16:640 – 50Google Scholar
  24. 24.
    Suh JW1, Seung KB, Gwak CH, Kim KS, Hong SJ, Park TH, Kim SH, Choi YJ, Joo SJ, Tahk SJ, Kim HS (2011) Comparison of antiplatelet effect and tolerability of Clopidogrel resinate with Clopidogrel bisulfate in patients with coronary heart disease (CHD) or CHD-equivalent risks: a phase IV, prospective, double-dummy, parallel-group, 4-week noninferiority trial. Clin Ther 33:1057–1068CrossRefPubMedGoogle Scholar
  25. 25.
    Borsiczky B1, Sarszegi Z, Konyi A, Szabados S, Gaszner B (2012) The effect of Clopidogrel besylate and Clopidogrelhydrogensulfate on platelet aggregation in patients with coronary artery disease: a retrospective study. Thromb Res 129:700–703CrossRefPubMedGoogle Scholar
  26. 26.
    Ashraf T1, Ahmed M, Talpur MS, Kundi A, Faruqui AM, Jaffery AH, Fareed A (2005) Competency profile of locally manufactured Clopidogrel Lowplat and foreign manufactured Clopidogrel Plavix in patients of suspected ischemic heart disease (CLAP-IHD). J Park Med Assoc 55:443–448Google Scholar
  27. 27.
    Park JB1, Koo BK, Choi WG, Kim SY, Park J, Kwan J, Park CG, Kim HS (2013) Comparison of antiplatelet efficacy and tolerability of Clopidogrelnapadisilate with Clopidogrel bisulfate in coronary artery disease patients after percutaneous coronary intervention: a prospective, multicenter, randomized, open-label, phase IV, noninferiority trial. Clin Ther 35:28–37 e4.CrossRefPubMedGoogle Scholar
  28. 28.
    Caldeira D1, Fernandes RM, Costa J, David C, Sampaio C, Ferreira JJ (2013) Branded versus generic Clopidogrel in cardiovascular diseases: a systematic review. J Cardiovasc Pharmacol 61:277 – 82CrossRefPubMedGoogle Scholar
  29. 29.
    Marcucci R, Paniccia R, Gosi AM, Gensini GF, Abbate R (2013) Bioequivalence in the real world is a complex challenge: the case of Clopidogrel. J Am Coll Cardiol 5(5):594–595. doi: 10.1016/j.jacc.2012.10.020 CrossRefGoogle Scholar
  30. 30.
    Kovacic JC1, Mehran R, Sweeny J, Li JR, Moreno P, Baber U, Krishnan P, Badimon JJ, Hulot JS, Kini A, Sharma SK (2014) Clustering of acute and subacute stent thrombosis related to the introduction of generic Clopidogrel. J Cardiovasc Pharmacol Ther 19:201–208CrossRefPubMedGoogle Scholar
  31. 31.
    Price MJ1, Nayak KR, Barker CM, Kandzari DE, Teirstein PS. Predictors of heightened platelet reactivity despite dual-antiplatelet therapy in patients undergoing percutaneous coronary intervention. Am J Cardiol 2009 May 15;103(10):1339–1343. doi: 10.1016/j.amjcard.2009.01.341
  32. 32.
    Gremmel T1, Steiner S, Seidinger D, Koppensteiner R, Panzer S, Kopp CW. Adenosine diphosphate-inducible platelet reactivity shows a pronounced age dependency in the initial phase of antiplatelet therapy with Clopidogrel. J Thromb Haemost 2010 Jan;8(1):37–42. doi: 10.1111/j.1538-7836.2009.03644.x
  33. 33.
    Paolo Zocca Liefke C., van der Heijden Marlies M., Kok, Marije M, Lowik Marc, Hartmann Martin G., Stoel J (Hans) W, Louwerenburg, Frits H.A.F., de Man, Gerard CM, Linssen Iris L., Knottnerus, Carine JM, Doggen K Gert van Houwelingen, Clemens von Birgelen. Clopidogrel or ticagrelor in acute coronary syndrome patients treated with newer-generation drug-eluting stents: CHANGE DAPT. EuroIntervention 2017Google Scholar

Copyright information

© Springer Science+Business Media, LLC 2017

Authors and Affiliations

  • Marta Rasia
    • 1
    • 5
  • Emilia Solinas
    • 1
  • Massimiliano Marino
    • 2
  • Paolo Guastaroba
    • 3
  • Alberto Menozzi
    • 1
  • Maria Alberta Cattabiani
    • 1
  • Iacopo Tadonio
    • 1
  • Rossana De Palma
    • 4
  • Luigi Vignali
    • 1
  1. 1.Unità Operativa di CardiologiaAzienda Ospedaliero-UniversitariaParmaItaly
  2. 2.AUSL di Reggio Emilia, Governo ClinicoRegione Emilia-RomagnaItaly
  3. 3.Agenzia Sanitaria Regionale, Servizio StatisticaRegione Emilia-RomagnaItaly
  4. 4.Direzione Generale Cura della Persona, Salute, Welfare, Servizio Assistenza OspedalieraRegione Emilia-RomagnaItaly
  5. 5.Division of CardiologyParma University HospitalParmaItaly

Personalised recommendations